Background: Two algorithms based on sequential measurements of liver and spleen
| INTRODUCTION
Portal hypertension contributes to the main complications of cirrhosis and to patients' mortality. 1 Clinically significant portal hypertension is defined as an hepatic venous pressure gradient (HVPG) ≥10 mm Hg. Above this threshold, portal hypertension can become symptomatic as patients can develop gastroesophageal varices and have an increased risk of clinical decompensation. HVPG measurement is considered the reference standard for evaluation of portal hypertension in patients with cirrhosis. 2 In patients without any history of cirrhosis decompensation, HVPG measurement can identify patients at risk of having, or of developing, gastroesophageal varices, and can help stratifying the risk of decompensation and of death following liver resection. 3 However, measurement of the HVPG is an invasive procedure that is only routinely available in expert centres. 4 Thus, there is need for non-invasive methods for the clinical assessment of portal hypertension in patients with cirrhosis.
Liver stiffness measurement using transient elastography has been extensively studied as a surrogate for HVPG ≥10 mm Hg and gastroesophageal varices. [5] [6] [7] Several parameters have also been proposed to improve the accuracy of liver stiffness for detecting HVPG ≥10 mm Hg and oesophageal varices, such as platelet count and spleen diameter. 8 Based on these results, Baveno VI guidelines proposed that upper gastrointestinal endoscopy could be avoided in patients with compensated cirrhosis and liver stiffness <20 kPa together with platelet count >150 G/L. 4 These results have been recently validated and expanded in a large cohort of patients with cirrhosis. [8] [9] [10] Limitations of transient elastography include the need of a dedicated device and a rate of failure or unreliable measurement ranging from 14% to 19%. 11 Two-dimensional real time shearwave elastography (2D-SWE) has been more recently developed. This technique is embedded in ultrasound devices and has higher success rates for liver stiffness and spleen stiffness measurement than transient elastography. 11, 12 2D-SWE could be an interesting tool for non-invasive estimation of portal hypertension in patients with cirrhosis. 3, [12] [13] [14] [15] [16] [17] Indeed, liver stiffness 12, [14] [15] [16] or spleen stiffness 14,15 measured using 2D-SWE correlate with HVPG. The diagnostic accuracy of liver stiffness measured using 2D-SWE for detection of HVPG ≥10 mm Hg is acceptable, with area under the receiver operating characteristic curves (AUROCs) ranging from 0.81 to 0.87, 12, [14] [15] [16] even in patients with decompensated disease. Recently, Jansen and colleagues proposed two sequential algorithms, using liver stiffness followed by spleen stiffness measurements using 2D-SWE, with excellent diagnostic accuracies for ruling-out 18 and ruling-in 15 HVPG ≥10 mm Hg in a population of 109 patients with cirrhosis of various etiologies.
Moreover, when combining the rule-out and rule-in algorithms, only 13% of the patients were in the indeterminate area requiring HVPG measurement. 15 However, these algorithms lack external validation.
Thus, the aim of this study was to assess independently in a large cohort of patients with cirrhosis the accuracy of these two algorithms. 
| Two-dimensional Shearwave elastography
2D-SWE was performed using the Aixplorer ultrasound system (Supersonic Imagine S.A., Aix-en-Provence, France) with an abdominal 3.5 MHz curved array probe (SC6-1), as recommended, 21 by three experienced radiologists (more than 50 exams). 2D-SWE measurements were performed within 7 days before or after HVPG measurement, in fasting patients. The operator was not aware of HVPG results when performing 2D-SWE.
2D-SWE measurements were performed as previously described.
14 Liver stiffness measurements were performed on the right lobe of the liver through the intercostal spaces with the patient in the supine position and the right arm maximally abducted. In the liver, the 2D-SWE box was placed in an area of the parenchyma free of large vessels, avoiding liver capsule. Spleen stiffness measurements were performed in the supine position with the left arm in maximum abduction and by placing the probe in the left intercostal spaces.
A 2D-SWE liver stiffness measurement was considered reliable when it fulfilled the following criteria: 22 (1) temporal stability of the selected liver area for at least 3 seconds before measurement; (2) two-dimensional quality confirmed by a homogenous colour in the region of interest; (3) a measurement region (Q-box) of at least 10 mm. 2D-SWE liver stiffness failure was defined as either no signal obtained or failure to obtain a reliable 2D-SWE measurement,
i.e, no temporal or spatial stability and/or Q-box <10 mm. 22 For 2D-SWE spleen stiffness, failure was defined as no signal obtained. 22 Up to three separate measurements were performed and results were reported as the mean of the total number of reliable measurements, as proposed by Jansen and colleagues. 15 To date, no minimum number of measurements and no definition of reliable measurements have been recommended by the manufacturer. However, quality criteria have been previously proposed for liver stiffness measurement 22 and were collected in our population, namely the number of reliable measurements, 14,23 the acquisition depth 14 and the variation coefficient 12, 14, 15 for patients with three available values. Patients with three measurements available, a variation coefficient <0.1 and an acquisition depth <5.6 cm were considered as having "highly reliable" liver stiffness measurements, as previously proposed. 14 In the absence of quality criteria for spleen stiffness, we considered patients with three measurements available and a variation coefficient <0.1 as having "highly reliable" spleen stiffness measurement. The acquisition depth was not included in criteria for "highly reliable" 2D-SWE spleen stiffness measurements.
| Statistical analysis
Quantitative variables were expressed as median and interquartile range (IQR). Comparisons between quantitative variables were performed using the t test or Mann-Whitney test for normally distributed and non-normally distributed variables, respectively.
Shapiro-Wilk test was used to determine whether or not the distribution of continuous variable was normal. Categorical data were presented as number (percentage), and were compared using the Chisquared test or Fisher's exact test, as appropriate. The relationships between liver stiffness, spleen stiffness and HVPG were characterised using the Spearman's correlation coefficient. The diagnostic performance of the 2 previously proposed algorithms 15, 18 were assessed using sensitivity, specificity, positive predictive value and negative predictive value, as well as the proportion of correctly classified patients. The discriminative value of liver stiffness and spleen stiffness for the identification of HVPG ≥10 mm Hg was assessed by measuring the AUROC. AUROCs were provided with their 95% confidence interval. All tests were two sided and 0.05 was considered to be significant. Data handling and analysis were performed with SPSS 20.0 (SPSS Inc, Chicago, IL, USA).
3 | RESULTS
| Patients
Between 2012 and 2016, 209 patients were prospectively enrolled ( Figure 1 ). Among these patients, 77 were part of a previously published study of our group. 12 Failure was observed for liver stiffness and spleen stiffness in 5 (2%) and 13 (6%) patients, respectively.
Both liver stiffness and spleen stiffness measurements using 2D-SWE were thus available in 191 patients. Indications for HVPG measurements were: pre-transplantation evaluation in 128 (67%)
patients, evaluation before liver resection in 31 (16%), and liver biopsy in patients with ascites and/or coagulation disorder in 32 (17%). Characteristics of the 191 included patients are summarised in Table 1 . Briefly, the proportion of patients with Child-Pugh class A, B and C cirrhosis was 39%, 29% and 31% respectively. Cause of cirrhosis was viral hepatitis in 48% of the patients and excessive alcohol consumption or metabolic syndrome in 45%. Seventy-eight per cent of the patients had HVPG ≥10 mm Hg. Ascites was present in 50% of the patients. Seventy-four patients (39%) had no history of decompensation of cirrhosis (Table 1) .
| Diagnostic performance of liver and spleen stiffness to estimate HVPG ≥10 mm Hg
The median (IQR) variation coefficient for liver stiffness was 0.10 (0.10-0.20) in the 187 patients with three reliable liver stiffness measurements.
The AUROCs (95% confidence interval (CI)) of liver stiffness and spleen stiffness for the diagnosis of HVPG ≥10 mm Hg are presented in Table 2 . Liver stiffness as well as spleen stiffness significantly correlated with HVPG ( Figure S1 ).
Liver stiffness was significantly higher in patients with HVPG In the paper by Jansen and colleagues, the first algorithm used liver stiffness <16.0 kPa and then spleen stiffness <26.6 kPa to rule-out HVPG ≥ 10 mm Hg. 18 In our cohort, among 22 patients with liver stiffness <16.0 kPa and then spleen stiffness <26.6 kPa, 8 (36%) had HVPG ≥10 mm Hg. Thus, the negative predictive was 64% (Figure 2A and Table 3 ).
The diagnostic accuracy of this algorithm was similar when restricting the analyses to the 74 patients without any history of decompensation of cirrhosis ( Figure 3A and Table S1 ), or to the 65 patients with "highly reliable" measurements ( Figure S2A and Table S2 ). The negative predictive value of the rule-out algorithm was 83% in patients with viral cirrhosis, while it was 29% in patients with alcohol or NASH-related cirrhosis (data not shown).
| Rule-in algorithm
In the paper by Jansen and colleagues, the second algorithm used liver stiffness >38.0 kPa, or liver stiffness ≤38.0 kPa but spleen stiffness >27.9 kPa, to rule-in HVPG ≥10 mm Hg. 15 In our F I G U R E 1 Flow chart. Out of the 1776 patients having undergone an HVPG measurement at our unit, 530 met the inclusion criteria. For 321 patients, 2D-SWE measurement could not be performed for organisational reasons or since the patients were not willing to participate. Two-hundred and nine patients were thus prospectively enrolled. Failure rates of liver stiffness and spleen stiffness were 2% (5/213) and 6% (13/213), respectively. Among the 191 patients included in the analysis, 65 met the criteria for (highly reliable) measurement for liver stiffness (ie, three measurements and variation coefficient < 0.1 and depth of measurement ≤5.6 cm) cohort, 49 patients had liver stiffness >38.0 kPa, and 72 patients had liver stiffness ≤38.0 kPa but spleen stiffness >27.9 kPa.
Among these 121 patients, 20 (17%) did not have HVPG ≥10 mm Hg, so that the positive predictive value was 83% ( Figure 2B and Table 3 ).
The diagnostic accuracy of this algorithm was similar when restricting the analyses to the 74 patients without any history of decompensation of cirrhosis ( Figure 3B and Table S1 ), or to the 65 patients with "highly reliable" measurements ( Figure S2B and Table S2 ). The positive predictive value of the rule-in algorithm was 77% in patients with viral cirrhosis, while it was 98% in patients with alcohol or NASH-related cirrhosis (data not shown).
| Combination of the two algorithms
Jansen and colleagues proposed a combination of the rule-in and the rule-out algorithms achieving a correct classification of 91.6% of the patients and avoiding HVPG measurement in 87% of the patients. 15 A grey zone corresponded to patients requiring HVPG measurement. In our cohort, using this combination, 28 patients (15%) were misclassified ( Figure 2C Figure 3C ), or to the 65 patients with "highly reliable" measurements ( Figure S2C ).
| DISCUSSION
This study evaluated in a large independent cohort of patients with cirrhosis the accuracy of two algorithms combining liver stiffness This algorithm used liver stiffness <16.0 kPa and then spleen stiffness <26.6 kPa to rule-out HVPG ≥10 mm Hg. In these patients HVPG ≥10 mm Hg was considered "very unlikely." (B) Algorithm to rule-in HVPG ≥10 mm Hg: this algorithm used liver stiffness >38.0 kPa, or liver stiffness ≤38.0 kPa but spleen stiffness >27.9 kPa. In these patients HVPG ≥10 mm Hg was considered "very likely". (C) The combination of the rule-out and the rule-in algorithm was proposed to avoid HVPG measurement in the patients with "very unlikely" HVPG ≥10 mm Hg, as well as in those with "very likely" HVPG ≥10 mm Hg followed by spleen stiffness measurements, using 2D-SWE, for the diagnosis of HVPG ≥10 mm Hg, and showed that these algorithms are not good enough to replace HVPG measurement or to base clinical decisions.
The first major finding of our study is an independent assessment of two algorithms combining liver stiffness followed by spleen stiffness measurements using 2D-SWE for the diagnosis of HVPG ≥10 mm Hg. As summarised in Table 4 , in the present cohort, diagnostic accuracy of these algorithms was much lower, the rule-out algorithm having a negative predictive value of 63% and the rule-in algorithm having a positive predictive value of 87%. These results have to be interpreted taking into account the high pretest probability of HVPG ≥10 mm Hg in our cohort (78%), meaning that the positive predictive value was favored over the negative predictive value in this study. These algorithms are thus insufficiently accurate to base the management of individual patients. Several reasons could explain this discrepancy. First, the diagnostic accuracy of these algorithms might have been overestimated when tested in the cohort they were derived from. Second, this variance might be due to differences in the patient populations. Indeed, patients included in our study had more severe cirrhosis than in the studies by Jansen and colleagues, as attested by a higher HVPG and MELD (Table 4) . Furthermore, in our population, the majority of the patients had HVPG measurement as part of liver transplantation evaluation, reflecting a more severe cirrhosis. The population of best interest for diagnosing HVPG ≥10 mm Hg is that of patients with compensated cirrhosis, as patients with decompensated cirrhosis all have HVPG ≥10 mm Hg. 4 However, restricting the analysis to patients without previous decompensation of cirrhosis did not improve our results, with AUROC for liver and spleen stiffness lower than in previous studies. 5 The high prevalence of hepatocellular carcinoma in patients without previous decompensation of cirrhosis in this study might account for this contrast. Indeed, the subanalyses we did showed lower AUROCs in patients with hepatocellular carcinoma, while previous studies only included patients without hepatocellular carcinoma. 14 This hypothesis will deserve further analyses since evaluating HVPG is particularly important in patients with compensated cirrhosis and hepatocellular carcinoma, a liver resection decision being influenced by portal hypertension level. 24 Another difference between our population and that published by Jansen and colleagues is the cause of liver disease. The majority of the patients included in the study by Jansen and colleagues had alcohol-related cirrhosis and 20% had hepatitis virus infection related cirrhosis, while in this study hepatitis virus infection was the leading cause and only one-third of the patients had an excessive alcohol consumption. 15 It is well known that the cause of chronic liver disease influences liver stiffness when evaluating fibrosis stages. 11 Interestingly, in the cohort by Jansen and colleagues, as well as in this study, the diagnostic accuracy of the rulein algorithm was much lower among patients with viral cirrhosis than in those with alcoholic cirrhosis. 25 This might explain the discrepancies between both studies and suggests that HVPG ≥10 mm Hg due to viral hepatitis is not adequately reflected by this algorithm.
The second major finding of our study is an independent validation of the reliability criteria proposed by previous studies in patients with cirrhosis. 14, 22 Indeed, in the subset of patients fulfilling the criteria for "highly reliable" measurement, the AUROC of liver stiffness for HVPG ≥10 mm Hg was 0.95, while it was 0.73 in the 126 patients who did not meet these criteria. These results are in line with a previous study of our group, in which we found that the smaller the variation coefficient, the higher the correlation between liver stiffness and HVPG. 12 Thus, our results strongly support that reliability criteria for liver stiffness measurement using 2D-SWE, in patients with cirrhosis, should include: (1) at least three reliable measurements and (2) SD/mean <10% and (3) depth measurement <5.6
cm. A limitation of these quality criteria is, however, only 34% of the overall population and 42% of the patients without a history of decompensation of cirrhosis fulfill them.
Another finding is that the AUROC of spleen stiffness for HVPG ≥10 mm Hg was much lower in this study than in previous reports by Jansen and colleagues, 15, 18 or by other groups. 5 This feature is likely linked to the much lower failure rate observed here than by Jansen and colleagues (6% vs 19%). These discrepancies point to the need for quality criteria for spleen stiffness measurement.
As the aim of this study was to independently assess in a large cohort of patients with cirrhosis the accuracy of these two algorithms proposed by Jansen and colleagues, we did not attempt to improve the accuracy of liver stiffness by 2D-SWE by adding other non-invasive parameters such as platelet count or spleen size. However, in a previous study from our group, we observed that LSPS (liver stiffness to platelet-to-spleen ratio score) 26 using LS by 2D-SWE did not perform better than liver stiffness alone for estimating HVPG ≥10 mm Hg. Forty percent of the patients included in this study have been included in this previous study by our group. 12 In conclusion, in patients with cirrhosis of various causes, the previously proposed algorithms, using sequential measurement of liver stiffness and then spleen stiffness using 2D-SWE are not good enough to rule-out or to rule-in HVPG ≥10 mm Hg in clinical practice or to make clinical decision.
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